Immune Systems Advisor

By Editorial Team | Originally published July 2022 | Fully revised and evidence-updated September 2026 | Reviewed against the 2026 ivermectin randomized-trial meta-analysis and current FDA/WHO guidance Quick Answer I-PREVENT is a pre- and post-exposure prevention protocol published by the Independent Medical Alliance (formerly the FLCCC), pairing common-sense measures with supplements — vitamin D, C, zinc, melatonin, elderberry, quercetin — and, more controversially, ivermectin and hydroxychloroquine. Vitamin D correction has genuine randomized-trial support for reducing respiratory infections, particularly in people who are deficient. Ivermectin does not : the largest and most recent synthesis of evidence, a 2026 meta-analysis of 40 randomized trials in over 23,000 people, found no statistically significant reduction in infection risk from prophylaxis and no meaningful treatment benefit — a conclusion shared by the FDA, WHO, and IDSA. Ivermectin and hydroxychlor...

Cold and flu season is not simply about having a thermometer and a box of cold medicine ready. The modern respiratory-virus landscape includes influenza, COVID-19, RSV and other viruses—and the evidence on how we should treat severe influenza is changing. Updated September 2026 • Evidence reviewed from CDC, WHO, Australian Living Evidence Collaboration and the 2026 REMAP-CAP influenza antiviral results Key update for 2026: A major REMAP-CAP randomized trial found that oseltamivir did not improve 90-day survival in critically ill patients with influenza and crossed a prespecified inferiority threshold. Australian interim guidance now recommends against oseltamivir in critically ill adults. This finding is highly important—but it does not mean that oseltamivir should be stopped in every person with influenza. Contents Why cold and flu season matters Cold vs flu: what is the difference? Common symptoms Who is at higher risk? Ho...